What is Psomagen?
Formerly known as Macrogen USA, Psomagen operates at the intersection of advanced biotechnology and clinical diagnostics. The company specializes in providing comprehensive genomics, epigenomics, metagenomics, transcriptomics, and proteomics services. With a commitment to high-quality integrative multiomics data, Psomagen utilizes CLIA-certified and CAP-accredited facilities to ensure rigorous standards in DNA, RNA, and protein analysis. Their business model is built upon making complex biological insights accessible and affordable, supported by sophisticated bioinformatics capabilities that streamline the path from raw data to actionable research outcomes. As a key player in the life sciences supply chain, Psomagen serves as a critical partner for organizations seeking to accelerate their discovery pipelines through precision laboratory services.
How much funding has Psomagen raised?
Psomagen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Psomagen
PPP
Public-Private Partnership
What's next for Psomagen?
With this late-stage capital infusion, Psomagen is well-positioned to scale its operational capacity and enhance its proprietary bioinformatics platforms. The strategic focus will likely shift toward deepening its penetration in the clinical diagnostics market while maintaining its stronghold in academic research. By optimizing its multiomics service delivery, the company is poised to capitalize on the increasing industry reliance on high-throughput sequencing and proteomic profiling. Future growth will be driven by the integration of emerging technologies that further reduce the cost and complexity of genomic analysis, ensuring Psomagen remains a leader in the rapidly evolving landscape of precision medicine and biotechnology services.
See full Psomagen company page
